Comparing two antibiotics for pneumonia in adults
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new antibiotic (omadacycline) compared to a standard one (moxifloxacin) for adults with community-acquired pneumonia. The goal is to see if the new drug is as safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have at least 3 breathing symptoms (cough, yellow mucus, chest pain, or shortness of breath).
- You have at least 2 signs of infection (fever, fast heart rate, fast breathing, or low blood pressure).
- You have not taken antibiotics for more than 24 hours in the last 3 days.
- You do not have a known drug-resistant infection or a lung abscess.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether omadacycline (an antibiotic) can safely and effectively treat a rare lung infection caused by Mycobacterium abscessus bacteria. If you have this infection, this study may help doctors understand if this antibiotic works better than current treatments.
This trial tests a new antibiotic called HRS-8427 for adults with bacterial pneumonia that started in the hospital or while on a ventilator. It may be an option if you need IV antibiotics and haven't already received long-term treatment for this infection.
This trial compares azithromycin and doxycycline for adults hospitalized with community-acquired pneumonia who are already getting a beta-lactam antibiotic. It aims to see which works better as an add-on treatment.
This trial compares different antibiotic strategies for children with pneumonia who are being treated as outpatients. The goal is to find the best approach to treat the infection and help your child recover.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This trial is testing a new way to choose antibiotics for people with COPD who get pneumonia and need intensive care. The goal is to find the best treatment using a personalized approach.
Hear when a new Community-acquired Bacterial Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.